Post-infection coronavirus immunity usually robust after 8 months, study shows
Scientists have been generally optimistic that these variants will be unable to escape the onslaught of the human immune system. But no one is taking any chances. Officials at the Centers for Disease Control and Prevention are ramping up a strain surveillance program to improve the genomic sequencing that allows scientists to study mutations.
The consensus is that the coronavirus would need a tremendous number of transmission-enhancing mutations in concert to evade natural or vaccine-induced immunity.
The full duration of immunity has to remain speculative for now, because the novel coronavirus has been circulating in human beings for barely a year and there isn’t long-term data
“I cannot tell you what it’s going to be looking like two years from now, because the virus hasn’t been around two years,” Sette said. “But from the looks of it, I wouldn’t be surprised if the immunity would last for years.”
COVID-19 vaccine development and a potential nanomaterial path forward
Inactivated vaccines (IVs) are heat or chemically inactivated pathogens or fractions thereof. These vaccine formulations are incapable of replication and safer than LAVs, but their inactivation results in lowered immunogenicity and requirement for multiple-dose regimens to establish long-lasting immunity; also, these vaccine formulations often require adjuvants to immunize the aging population due to immune senescence37. While IVs have better stability profiles compared to LAVs, they still require a cold chain. Several COVID-19 IVs are in development, with the first clinical trial approved recently for Sinovac.
Ronald Kempers and the potential of a new COVID-19 nasal vaccine
We’re aiming to develop a safe and highly effective COVID-19 vaccine. The idea is that it could be easily administered to all age groups, but in particular immunocompromised and elderly patients
Market Data 
Markets 
AI
